Who owns Paratek Pharmaceuticals?

Tip: Access positions for across all investors

Analyze quarterly positions in Paratek Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Top investors of Paratek Pharmaceuticals stock

Who bought or sold Paratek Pharmaceuticals this quarter?

There are no current stakeholders of Paratek Pharmaceuticals.

This is normal when the security:

  • Has been acquired or taken private
  • Has merged with another entity
  • Has changed its name and has a new CUSIP (and/or symbol)
  • Has been delisted and the ticker has changed

Please use Search to find the security you were looking for.

Who sold out of Paratek Pharmaceuticals?

Fund or Company Name Date Sold Shares Held Valued At
Eugene S. Stark Jun 2023 1.8M $4.1M
Rock Springs Capital Management Jun 2023 1.7M $3.8M
Eversept Partners Jun 2023 1.3M $2.9M
BlackRock Jun 2023 895k $2.0M
Natixis Jun 2023 492k $1.1M
Geode Capital Management Jun 2023 440k $972k
Gabelli Funds Jun 2023 370k $817k
Hunting Hill Global Capital Jun 2023 361k $798k
Gabelli Securities Jun 2023 307k $678k
State Street Corporation Jun 2023 216k $478k
Renaissance Technologies Jun 2023 130k $286k
Trellus Management Company Jun 2023 127k $281k
Susquehanna International Jun 2023 118k $261k
Northern Trust Jun 2023 114k $253k
Morgan Stanley Jun 2023 111k $246k
Yakira Capital Management Jun 2023 100k $221k
Water Island Capital Jun 2023 85k $187k
XTX Topco Jun 2023 63k $139k
Kathmere Capital Management Jun 2023 30k $66k
Teton Advisors Jun 2023 25k $55k
GAMCO Asset Management Jun 2023 19k $42k
LPL Financial Jun 2023 11k $23k
FMR Jun 2023 420.00 $927.990000